Therefore, our data suggested an important role of gal-1 in CD133+ lung cancer stem cells, which might be a potential target for treatment of lung adenocarcinoma and a marker for prognosis of lung cancer patients. This evidence concerns the gene PROM1 and lung adenocarcinoma.